AnorMed has completed enrollment of patients for one of is Phase III clinical trials for with MOZOBIL for stem cell transplant as treatment for Multiple Myeloma, a cancer of the plasma cells. MOZOBIL is a stem cell mobilizer used in stem cell transplants, triggering the movement of stem cells from the bone marrow into the circulating blood. Once in the blood, the stem cells can be collected for use in a stem cell transplant, thereby making treatment of patients with their own stem cells possible.

According to the Special Protocol Assessment with the FDA,

the most recently enrolled patients will undergo their transplants over the next 4-6 weeks with a subsequent 100 day follow-up period required. The MM trial design also allows physicians to request, upon enrollment, that a patient has the option to have a second or "tandem" transplant should they not go into complete remission. Physicians have up to 6 months from the first transplant to perform a second transplant if required. The 100 day follow-up period would then commence from the date of the second transplant. The results of the study will be unblinded once all patients enrolled have completed their 100 day follow-up.

AnorMed is also still recruiting patients to test MOZOBIL for treating non-Hodgkin's lymphoma (NHL).

For more details, see AnorMed's press release.